143 related articles for article (PubMed ID: 38549625)
1. Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers.
Fan J; Thanedar S; Ovechko V; Jana B
Case Rep Oncol; 2024; 17(1):517-523. PubMed ID: 38549625
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of multiple T antigens: CD4, CD5, and CD8 on diffuse large B-cell lymphoma.
Sangle NA; Miles RR; Kelley TW; Perkins SL
Appl Immunohistochem Mol Morphol; 2014; 22(10):e45-8. PubMed ID: 24185124
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
5. CD7 Positive Diffuse Large B-Cell Lymphoma Arising in a Background of Follicular Lymphoma: A Case Report and Review of the Literature.
Vali Betts E; Rashidi HH
Case Rep Hematol; 2016; 2016():5415974. PubMed ID: 27774324
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract][Full Text] [Related]
7. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Am J Clin Pathol; 2009 Mar; 131(3):339-46. PubMed ID: 19228640
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration.
Carulli G; Stacchini A; Marini A; Ciriello MM; Zucca A; Cannizzo E; Aliberti S; Demurtas A; Novero D; Calcagno L; Callegari T; Petrini M
Am J Clin Pathol; 2009 Aug; 132(2):186-90; quiz 306. PubMed ID: 19605812
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7.
Sangle NA; Agarwal AM; Smock KJ; Leavitt MO; Warnke R; Bahler D; Perkins SL
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):579-83. PubMed ID: 21836500
[TBL] [Abstract][Full Text] [Related]
13. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
14. Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.
Zhang X; Sun M; Zhang L; Shao H
Int J Clin Exp Pathol; 2013; 6(5):985-9. PubMed ID: 23638236
[TBL] [Abstract][Full Text] [Related]
15. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
18. CD5+ diffuse large B-cell lymphoma: a narrative review.
Durani U; Ansell SM
Leuk Lymphoma; 2021 Dec; 62(13):3078-3086. PubMed ID: 34284686
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
20. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma.
Nakamura N; Hashimoto Y; Kuze T; Tasaki K; Sasaki Y; Sato M; Abe M
Lab Invest; 1999 Aug; 79(8):925-33. PubMed ID: 10462030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
